Pharmaceutical-grade cannabidiol oral solution made by INSYS Therapeutics was generally well-tolerated-even at high doses-as an investigational treatment for refractory pediatric epilepsy, according to new clinical data from a long-term safety study presented yesterday at the American Epilepsy Society 2018 annual meeting. “The results of this study support the promising safety profile of CBD oral solution from INSYS in the context of treating pediatric patients with intractable seizures due to epilepsy,” said James W. Wheless, M.D., professor and chief of pediatric neurology at the University of Tennessee Health Science Center in Memphis, where he directs the Neuroscience Institute & Le Bonheur Comprehensive Epilepsy at Le Bonheur Children’s Hospital and holds the Le Bonheur Chair in Pediatric Neurology. “In addition, these long-term safety data are consistent with those from other studies of CBD in refractory pediatric epilepsy.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.